ArticleNeurosciences (Riyadh, Saudi Arabia)2025
Quality of life, depression, and anxiety in brain tumor patients following surgical resection at a tertiary care center.
Article in Neurosciences (Riyadh, Saudi Arabia), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo address the gap in understanding post-surgical quality of life, depression, and anxiety among brain tumor patients in Saudi Arabia.
methodsThis cross-sectional study was conducted at King Abdulaziz Medical City in Jeddah, Kingdom of Saudi Arabia. A total of 160 adult brain tumor patients who underwent surgical resection between January 2021 and October 2024 were included. Quality of life (QoL) was assessed using the Functional Assessment of Chronic Illness Therapy (FACIT) questionnaire, and anxiety and depression were measured using the Hospital Anxiety and Depression Scale (HADS).
resultsAmong the 160 patients, high-grade gliomas were the most common tumor type (35%), followed by meningiomas (27.5%). WHO grade 4 tumors were most prevalent (43.12%), followed by grade 1 (35.62%). Patients with high-grade gliomas and metastatic tumors reported the lowest QoL scores. Interestingly, low-grade glioma patients showed higher levels of anxiety (44.4%) and depression (33.3%). In contrast, patients with meningiomas and pituitary adenomas had better QoL outcomes.
conclusionPatients with high-grade gliomas experienced poorer QoL postoperatively. However, good QoL is still achievable, particularly among those with benign tumors such as meningiomas and pituitary adenomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.